Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIASP aspirin crossover study in type 2 diabetes with subclinical atherosclerosis
NL-OMON23321Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of aspirin in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Markers of vascular wall inflammation, High-sensitivity C-reactive protein and 1 more. Started Apr 2005; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on NL-OMON23321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23321.